RJA
TDOC icon

Raymond James & Associates’s Teladoc Health TDOC Stock Holding History

Raymond James & Associates’s Portfolio TDOC Stock Details TDOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$301K Sell
32,780
-5,461
-14% -$45.2K ﹤0.01% 3400
2024
Q2 		$374K Sell
38,241
-3,114
-8% -$38K ﹤0.01% 3246
2024
Q1 		$624K Sell
41,355
-134,255
-76% -$2.44M ﹤0.01% 2917
2023
Q4 		$3.78M Sell
175,610
-52,628
-23% -$971K ﹤0.01% 1709
2023
Q3 		$4.24M Buy
228,238
+2,029
+0.9% +$47.4K ﹤0.01% 1563
2023
Q2 		$5.73M Buy
226,209
+6,907
+3% +$174K ﹤0.01% 1391
2023
Q1 		$5.68M Buy
219,302
+11,926
+6% +$319K ﹤0.01% 1383
2022
Q4 		$4.9M Sell
207,376
-16,126
-7% -$435K ﹤0.01% 1411
2022
Q3 		$5.67M Buy
223,502
+432
+0.2% +$15.2K 0.01% 1286
2022
Q2 		$7.41M Sell
223,070
-12,126
-5% -$515K 0.01% 1152
2022
Q1 		$17M Buy
235,196
+13,018
+6% +$938K 0.01% 779
2021
Q4 		$20.4M Sell
222,178
-22,241
-9% -$2.66M 0.02% 734
2021
Q3 		$31M Sell
244,419
-5,049
-2% -$735K 0.03% 515
2021
Q2 		$41.5M Sell
249,468
-12,009
-5% -$1.95M 0.04% 411
2021
Q1 		$47.5M Sell
261,477
-21,727
-8% -$5.04M 0.05% 334
2020
Q4 		$56.6M Buy
283,204
+1,385
+0.5% +$282K 0.06% 259
2020
Q3 		$61.8M Buy
281,819
+22,996
+9% +$4.87M 0.08% 208
2020
Q2 		$49.4M Buy
258,823
+16,711
+7% +$2.93M 0.07% 245
2020
Q1 		$37.5M Sell
242,112
-482
-0.2% -$56.1K 0.06% 261
2019
Q4 		$20.3M Sell
242,594
-4,993
-2% -$380K 0.03% 574
2019
Q3 		$16.8M Buy
247,587
+11,777
+5% +$775K 0.02% 619
2019
Q2 		$15.7M Buy
235,810
+22,078
+10% +$1.29M 0.02% 639
2019
Q1 		$11.9M Buy
213,732
+29,746
+16% +$1.82M 0.02% 727
2018
Q4 		$9.12M Sell
183,986
-33,291
-15% -$2.04M 0.02% 796
2018
Q3 		$18.8M Sell
217,277
-10,956
-5% -$781K 0.03% 556
2018
Q2 		$13.2M Buy
228,233
+5,777
+3% +$282K 0.02% 678
2018
Q1 		$8.96M Buy
222,456
+106,743
+92% +$4.03M 0.02% 840
2017
Q4 		$4.03M Buy
115,713
+3,589
+3% +$119K 0.01% 1246
2017
Q3 		$3.72M Buy
112,124
+52,507
+88% +$1.72M 0.01% 1245
2017
Q2 		$2.07M Buy
59,617
+9,345
+19% +$272K ﹤0.01% 1554
2017
Q1 		$1.26M Buy
+50,272
New +$1.05M ﹤0.01% 1828

Other funds holding TDOC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Raymond James & Associates's TDOC Position: Q3 2024 in Review

Raymond James & Associates reduced its Teladoc Health (TDOC) stake by 14% in Q3 2024, selling an estimated $45.2K and leaving 32,780 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #3400.

Raymond James & Associates first reported a position in TDOC in Q1 2017 and has held it in 31 quarters since. The position peaked at $61.8M in Q3 2020. 366 funds tracked by Wall St. Rank hold TDOC as of Q3 2024.

  • Raymond James & Associates held 32,780 shares of Teladoc Health worth $301K as of Q3 2024.
  • Raymond James & Associates sold 5,461 Teladoc Health shares in Q3 2024, an estimated $45.2K.
  • Teladoc Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3400 holding.
  • Raymond James & Associates first reported a position in Teladoc Health in Q1 2017 and has held it in 31 quarters since.
  • Raymond James & Associates's Teladoc Health position peaked at $61.8M in Q3 2020.
  • 366 funds tracked by Wall St. Rank held Teladoc Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.